NCT05991206View on ClinicalTrials.gov

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

RecruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

August 1, 2026

Conditions

NSCLC

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER